TCT Connect 2020 Discussion: The VOYAGER PAD Study

Published: 03 Nov 2020

  • Views:

    Views Icon 414
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

Dr Mirvat Alasnag (The King Fahd Armed Forces Hospital, Jeddah, KSA) and Dr Connie N Hess (University of Colorado School of Medicine, Aurora, CO, US) discuss the results of the sub-analysis of the VOYAGER PAD Study.
The VOYAGER PAD trial showed that rivaroxaban/aspirin was superior to aspirin at preventing major adverse limb and cardiovascular events.
Dr Hess describes the design of the secondary analysis. Dr Alasnag and Dr Hess discuss how the results of this trial could impact the use of drug-coated devices in the future. 

Recorded remotely from Jeddah and Aurora, 2020.

Recording Editor: Natascha Wienand
Editor: Mirjam Boros